Jefferies Financial Group Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)

Equities researchers at Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $23.00 price target on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 175.12% from the stock’s previous close.

A number of other brokerages have also issued reports on AVTX. Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 price objective on the stock. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective on the stock. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company. Finally, HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Price Performance

AVTX opened at $8.36 on Tuesday. The business’s 50-day moving average price is $7.55 and its two-hundred day moving average price is $9.13. Avalo Therapeutics has a 1 year low of $4.60 and a 1 year high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $114,000. Walleye Capital LLC acquired a new stake in Avalo Therapeutics in the 4th quarter valued at about $145,000. Northern Trust Corp acquired a new stake in Avalo Therapeutics in the 4th quarter valued at about $168,000. Finally, Bank of Montreal Can bought a new position in Avalo Therapeutics during the fourth quarter worth about $446,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.